Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

due to the limitations experienced with prior research utilising interleukin-12 (IL-12), which is often considered to be one of the “holy grails” in cancer immunotherapy. IL-12 is a powerful ...

Department of Immunology, Institute of Biostructure, Medical University of Warsaw, Warsaw, Poland ...

Human interleukin‐12 (IL‐12, p70) is an early pro‐inflammatory cytokine, comprising two disulfide‐linked subunits, p35 and p40. We solved the crystal structures of monomeric human p40 at 2.5 Å and the ...

Background/Aim—Interleukin (IL) 12 is involved in the mucosal response during intestinal inflammation but its role is not fully understood. The response of human lamina propria T lymphocytes (T-LPL) ...

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a dendritic-cell–natural-killer-cell circuit that suppresses leptomeningeal metastases in mouse ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

Market LaunchFormycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada 27.05.2025 / 14:30 CET/CESTThe issuer is solely responsible for ...

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab ...

KaliVir Immunotherapeutics has concluded the first cohort in the Phase I/Ib STEALTH-001 trial evaluating VET3-TGI for ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...